🚀 VC round data is live in beta, check it out!
Lisata Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Lisata Therapeutics and similar public comparables like Vivoryon Therapeutics, SCYNEXIS, Rallybio, RenovoRx and more.
Lisata Therapeutics Overview
About Lisata Therapeutics
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The group has one operating segment, the research and development of its investigational drug product.
Founded
1980
HQ
Employees
26
Website
Sectors
Financials (LTM)
EV
$23M
Lisata Therapeutics Financials
Lisata Therapeutics reported last 12-month revenue of —.
Revenue (LTM)
Lisata Therapeutics P&L
In the most recent fiscal year, Lisata Therapeutics reported revenue of $170K and EBITDA of ($18M).
Lisata Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $170K | XXX | XXX | XXX |
| EBITDA | — | XXX | ($18M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (10625%) | XXX | XXX | XXX |
| EBIT Margin | — | XXX | (10711%) | XXX | XXX | XXX |
| Net Profit | — | XXX | ($17M) | XXX | XXX | XXX |
| Net Margin | — | XXX | (9756%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Lisata Therapeutics Stock Performance
Lisata Therapeutics has current market cap of $45M, and enterprise value of $23M.
Market Cap Evolution
Lisata Therapeutics' stock price is $5.01.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $23M | $45M | 0.2% | XXX | XXX | XXX | $-1.84 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialLisata Therapeutics Valuation Multiples
Lisata Therapeutics trades at 137.2x EV/Revenue multiple, and (1.3x) EV/EBITDA.
EV / Revenue (LTM)
Lisata Therapeutics Financial Valuation Multiples
As of April 11, 2026, Lisata Therapeutics has market cap of $45M and EV of $23M.
Equity research analysts estimate Lisata Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Lisata Therapeutics has a P/E ratio of (2.7x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $45M | XXX | $45M | XXX | XXX | XXX |
| EV (current) | $23M | XXX | $23M | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 137.2x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (1.3x) | XXX | XXX | XXX |
| EV/EBIT | — | XXX | (1.3x) | XXX | XXX | XXX |
| P/E | — | XXX | (2.7x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (1.5x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Lisata Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Lisata Therapeutics Margins & Growth Rates
Lisata Therapeutics' revenue in the last fiscal year declined by (83%).
Lisata Therapeutics' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.7M for the same period.
Lisata Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | (83%) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (10625%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (19%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.7M | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 6135% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 4676% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 10811% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Lisata Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SCYNEXIS | XXX | XXX | XXX | XXX | XXX | XXX |
| Rallybio | XXX | XXX | XXX | XXX | XXX | XXX |
| RenovoRx | XXX | XXX | XXX | XXX | XXX | XXX |
| Corline Biomedical | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Lisata Therapeutics M&A Activity
Lisata Therapeutics acquired XXX companies to date.
Last acquisition by Lisata Therapeutics was on XXXXXXXX, XXXXX. Lisata Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Lisata Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialLisata Therapeutics Investment Activity
Lisata Therapeutics invested in XXX companies to date.
Lisata Therapeutics made its latest investment on XXXXXXXX, XXXXX. Lisata Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Lisata Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Lisata Therapeutics
| When was Lisata Therapeutics founded? | Lisata Therapeutics was founded in 1980. |
| Where is Lisata Therapeutics headquartered? | Lisata Therapeutics is headquartered in United States. |
| How many employees does Lisata Therapeutics have? | As of today, Lisata Therapeutics has over 26 employees. |
| Who is the CEO of Lisata Therapeutics? | Lisata Therapeutics' CEO is David J. Mazzo. |
| Is Lisata Therapeutics publicly listed? | Yes, Lisata Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of Lisata Therapeutics? | Lisata Therapeutics trades under LSTA ticker. |
| When did Lisata Therapeutics go public? | Lisata Therapeutics went public in 1999. |
| Who are competitors of Lisata Therapeutics? | Lisata Therapeutics main competitors are Vivoryon Therapeutics, SCYNEXIS, Rallybio, RenovoRx. |
| What is the current market cap of Lisata Therapeutics? | Lisata Therapeutics' current market cap is $45M. |
| What is the current EV/Revenue multiple of Lisata Therapeutics? | Current revenue multiple of Lisata Therapeutics is 137.2x. |
| Is Lisata Therapeutics profitable? | No, Lisata Therapeutics is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.